Arvanitis CD et al. |
Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. |
2018 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:30150398
|
Moore KN et al. |
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. |
2018 |
Gynecol. Oncol. |
pmid:30093227
|
Wang L et al. |
STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer. |
2018 |
Cancer Sci. |
pmid:30076657
|
Jin W et al. |
LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma. |
2018 |
Bioanalysis |
pmid:29863890
|
Menchon G et al. |
A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin. |
2018 |
Nat Commun |
pmid:29844393
|
Johnson TA and Singla DK |
Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker. |
2018 |
Can. J. Physiol. Pharmacol. |
pmid:29842793
|
Barok M et al. |
Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. |
2018 |
BMC Cancer |
pmid:29720111
|
Sakai H et al. |
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. |
2018 |
Breast Cancer |
pmid:29700710
|
Escrivá-de-Romanà S et al. |
HER2-positive breast cancer: Current and new therapeutic strategies. |
2018 |
Breast |
pmid:29631097
|
Moore KN et al. |
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. |
2018 |
Future Oncol |
pmid:29424243
|
Ricciardi GRR et al. |
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review. |
2018 |
BMC Cancer |
pmid:29370839
|
Yeo W et al. |
Efficacy and tolerability of trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer. |
2018 |
Hong Kong Med J |
pmid:29326401
|
Gligorov J et al. |
Emilia: use cunning to survive cancer. |
2018 |
Chin Clin Oncol |
pmid:29307196
|
Mohamed HE et al. |
Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol. |
2018 |
J Pharm Biomed Anal |
pmid:29258046
|
Doroshow DB and LoRusso PM |
Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. |
2018 |
Future Oncol |
pmid:29214842
|
Hurvitz SA et al. |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. |
2018 |
Lancet Oncol. |
pmid:29175149
|
Ricci F and Le Tourneau C |
Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence? |
2018 |
Chin Clin Oncol |
pmid:29156892
|
Moore KN et al. |
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. |
2018 |
Future Oncol |
pmid:29098867
|
Zuradelli M et al. |
Never too old to fight breast cancer: A case report. |
2018 |
Medicine (Baltimore) |
pmid:29489698
|
Madden R et al. |
Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
. |
2018 |
Int J Clin Pharmacol Ther |
pmid:29231164
|
Vilela MD et al. |
Progressively Enlarging Cerebellar Hematoma Concurrent with T-DM1 Treatment. |
2018 |
World Neurosurg |
pmid:29274446
|
Nittoli T et al. |
Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids. |
2018 |
Bioorg. Med. Chem. |
pmid:29605304
|
Menderes G et al. |
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. |
2017 |
Clin. Cancer Res. |
pmid:28679774
|
Montemurro F |
Trastuzumab emtansine in HER2-positive metastatic breast cancer. |
2017 |
Lancet Oncol. |
pmid:28526537
|
Li C et al. |
A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function. |
2017 |
Clin Pharmacokinet |
pmid:27995530
|
Takegawa N et al. |
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. |
2017 |
Int. J. Cancer |
pmid:28677116
|
Mescher C et al. |
Left Ventricular Ejection Fraction Screening and Clinical Decision-making in Metastatic HER2-positive Breast Cancer. |
2017 |
Anticancer Res. |
pmid:28668870
|
Kmietowicz Z |
NICE approves trastuzumab emtansine after deal with drug company. |
2017 |
BMJ |
pmid:28623237
|
Krop IE et al. |
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. |
2017 |
Lancet Oncol. |
pmid:28526538
|
Diéras V et al. |
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. |
2017 |
Lancet Oncol. |
pmid:28526536
|
Morimura O et al. |
Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models. |
2017 |
Biochem. Biophys. Res. Commun. |
pmid:28526406
|
Menderes G et al. |
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. |
2017 |
Gynecol. Oncol. |
pmid:28473206
|
Moore KN et al. |
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors. |
2017 |
Cancer |
pmid:28440955
|
Ito K et al. |
Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer. |
2017 |
Bioconjug. Chem. |
pmid:28402624
|
Sun X et al. |
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. |
2017 |
Bioconjug. Chem. |
pmid:28388844
|
Eckelmann D et al. |
Spatial profiling of maytansine during the germination process of Maytenus senegalensis seeds. |
2017 |
Fitoterapia |
pmid:28385670
|
Thuss-Patience PC et al. |
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. |
2017 |
Lancet Oncol. |
pmid:28343975
|
Beck A et al. |
Strategies and challenges for the next generation of antibody-drug conjugates. |
2017 |
Nat Rev Drug Discov |
pmid:28303026
|
Zhong P et al. |
αβ integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo. |
2017 |
Int J Nanomedicine |
pmid:29138558
|
Li Y et al. |
EpCAM aptamer-functionalized polydopamine-coated mesoporous silica nanoparticles loaded with DM1 for targeted therapy in colorectal cancer. |
2017 |
Int J Nanomedicine |
pmid:28894364
|
Chen SC et al. |
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens. |
2017 |
Br J Clin Pharmacol |
pmid:28733983
|
Iwamoto N et al. |
LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. |
2017 |
J Pharm Biomed Anal |
pmid:28648785
|
Seidel K et al. |
Synthesis of Magnetic-Nanoparticle/Ansamitocin Conjugates-Inductive Heating Leads to Decreased Cell Proliferation In Vitro and Attenuation Of Tumour Growth In Vivo. |
2017 |
Chemistry |
pmid:28585348
|
Lynce F et al. |
SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. |
2017 |
Oncologist |
pmid:28314836
|
Janjigian YY and Braghiroli MI |
Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer. |
2017 |
Surg. Oncol. Clin. N. Am. |
pmid:28279471
|
Stefan N et al. |
Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. |
2017 |
Mol. Cancer Ther. |
pmid:28258164
|
Wang H et al. |
Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity. |
2017 |
Chem. Commun. (Camb.) |
pmid:28195282
|
Zhong P et al. |
αβ Integrin-targeted reduction-sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo. |
2017 |
J Control Release |
pmid:27986551
|
Wang LL et al. |
A Bio-Chemosynthetic Approach to Superparamagnetic Iron Oxide-Ansamitocin Conjugates for Use in Magnetic Drug Targeting. |
2017 |
Chemistry |
pmid:27935144
|
Lin J and Zhong JJ |
Proteomic studies on anti-tumor agent ansamitocin P-3 producer Actinosynnema pretiosum in response to ammonium and isobutanol. |
2017 |
Bioprocess Biosyst Eng |
pmid:28382459
|